The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.

Dermatology Clinical Trials Unit

Stephanie Farris, Clinical Research Coordinator, Main Campus
Phone: 314-747-8694 Fax: 314-362-6080

Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator, All sites
Phone: 314-362-8171 Fax: 314-362-6080

Jianrong Yang, Clinical Research Coordinator, Main Campus
Phone: 314-273-3737 Fax: 314-362-6080

Milan Anadkat, MD, Director, Clinical Trials Unit 

Currently Enrolling Trials

Dr. Milan Anadkat- (COH)

A pragmatic study of home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis (Short Title: Light Treatment Effectiveness (LITE) Study) Identifier: NCT03726489

The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy with Clindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating Fields Identifier: NCT04469075

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) Identifier: NCT04088318

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (CLEER) Identifier: NCT05639933

A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) Identifier: NCT05279846

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants with Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2) Identifier: NCT05620836

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (MORPHEUS) Identifier: NCT05696392

Dupilumab In Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-seVere Eczema tRial (DISCOVER) Identifier: NCT05590585

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (ADmirable) Identifier: NCT05372419

Dr. Amy Musiek- (COH)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 (Deucravacitinib; TYK2 inhibitor) in Subjects with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Identifier: NCT04857034

Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis Identifier: NCT03181893

Real World Observational Study of Poteligeo in Adult Patients with Mycosis Fungoides and SS (PROSPER) Identifier: NCT05455931